Research status of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes mellitus with heart failure with preserved ejection fraction

VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病合并射血分数保留心力衰竭的研究状况
Author: Ming-Yan LIU ¹ ; Bing-Qi ZHANG ; Hu-Hu LI ; Nai-Ru YUN ; Si-Miao FAN ; Rong-Rong YANG ; Rui-Ying GUO ; Yong-Na DAI
Author Information

1. 天津中医药大学中医学院,天津 301617
Keywords: sodium-glucose co-transporter protein 2 inhibitor; heart failure with preserved ejection fraction; type 2 diabetes mellitus
From: The Chinese Journal of Clinical Pharmacology 2024;40(13):1977-1981
CountryChina
Language:Chinese
Abstract: Sodium-glucose co-transporter protein 2 inhibitor(SGLT2i)has steadily demonstrated benefits in the treatment of type 2 diabetes complicated with cardiovascular diseases based on evidence-based medicine,but its precise mechanism is yet unknown.We identified type 2 diabetes patients with HFpEF by searching PubMed,Web of Science,China knowledge network(CNKI),and other databases.We then summarized the pathological mechanism of HFpEF caused by type 2 diabetes.At the same time,to link to evidence-based medical,we explored the future of SGLT2i in clinical application.